Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Ixabepilone, with or without estramustine phosphate, is well tolerated and has antitumor activity in patients with castrate metastatic prostate cancer.